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were linearly related to PVR (Table)however the highest correlation with the severity of
PVR was seen with the maximum diameter (r20.48, p0.001), mean diam-
eter(r20.47, p0.0001), average diameter (r20.48, p0.0001) or the annular area
(r20.48, p0.0001).
Conclusions: This study demonstrates that 3DE measurements of the aortic annulus are
feasible and are better predictors of PVR after TAVR than 2D sagittal diameter and should
be incorporated into the algorithm for balloon-expandable transcatheter valve sizing.
Comparison of 2DE and 3DE Measurements
Cover Index NoPD (n23) PD (n35) p-value
r2 for linear
measure
2DE Sagittal 10.14 4.02 6.89 3.24 0.002 0.26
(p  0.001)
3DE Minimum 16.19 6.39 10.88 4.91 0.001 0.36
(p0.0001)
3DE Maximum 8.67 7.87 -2.74 6.50  0.001 0.48
(p0.0001)
3DE Mean 12.44 6.65 4.07 4.71  0.001 0.47
(p0.0001)
3DE Average 11.50 6.11 2.68 4.93  0.001 0.48
(p0.0001)
3DE Area 23.09 10.32 7.91 9.14  0.001 0.48
(p0.0001)
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Background: Despite excellent outcome after transcatheter aortic valve implantation
(TAVI), paravalvular leaks may occur. Objective of this study was to evaluate annulus
sizing by 3-D computed tomography (CT) for prediction of paravalvular leaks after TAVI,
and to compare CT with transesophageal (TEE) and intracardiac echocardiography (ICE).
Methods: In 88 patients (mean, 83yrs) with severe aortic stenosis who underwent TAVI,
transesophageal (TEE), intracardiac echocardiography (ICE) and ECG-gated CT-
Angiography were performed before device implantation. Two-(ML/AP), three-annulus
diameter (RC/LC/NC) and the annulus area were measured on CTA. “Undersizing” was
defined as CT annulus–prosthetic heart valve (PHV) size; “annulus eccentricity” as
AP/ML-annulus diameter ratio. Post-procedural echocardiography was performed imme-
diately after, and at 1, 3,6, 12 and 24 month after the procedure and severity of
paravalvular leaks graded.
Results: Of 88 implanted prosthetic heart valves (PHV) 22 (25%) had none, 46 (52.3%)
mild, 11 (12.5%) mild-to-moderate, 9 (10.2%) moderate or moderate-to-severe, and 0%
severe leaks. Both TEE and ICE measured smaller mean annulus diameters than CT
(mean:-2,84mm and -2.19mm, resp., p0.01). Overall, 53% of PHV were undersized, in
only 3/22 (14%) patients with no leaks and in 35/66 (53%) with leaks. Undersizing was
higher in those with leaks as compared to those without (1mm vs 0.2mm, p0.01). No
difference between mild and moderate-to-severe (1mm vs. 1.2mm, p0.64) leaks were
found for the mean of 3-annulus diameters. The annulus area undersizing was higher in
patients with leaks than in those without (0.44cm2 vs 0.14cm2, p0.05), however the
annulus eccentricity index was not different (0.82 vs. 0.82, p0.06). If applying the 3-
instead of 2-diameter annular CT measurements, 4 (5%) patients without leaks and 2 (2%)
with leaks were reclassified as not-undersized and undersized, respectively.
Conclusions: PHV undersizing relative to CT annulus dimensions is associated with
paravalvular leaks after TAVI, but not annulus eccentricity. Three-diameter annulus
sizing by CT may be more accurate than the two-diameter method.
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Background: To develop computed tomography (CT) sizing guidelines for transcatheter
aortic valve replacement (TAVR). CT annular measurements are predictive of paraval-
vular regurgitation post TAVR; a predictor of mortality and morbidity.
Methods: The Vancouver CT sizing guidelines aim to ensure routine transcatheter heart
valve (THV) over sizing of the aortic annulus (range:1-20%, target 10-15%). Percentage
of over sizing is defined as (THV external area/annular area-1) x 100. 120 consecutive
patients underwent CT prior to TAVR with balloon expandable valves using transesoph-
ageal echocardiography (TEE) sizing recommendations. The Vancouver CT sizing
guidelines recommended prosthesis size was compared to the actual size implanted.
Results: As compared to TEE sizing recommendations, the Vancouver CT sizing
guidelines recommended a larger valve in 33.3% (40/120), no change in valve size in
55.8% (67/120) and a smaller valve in 10.8%(13/120). In patients where CT guidelines
would have recommended a larger valve, the incidence of at least moderate paravalvular
regurgitation was 25% (10/40), compared to only 4.5% (3/67, p0.01) when both TEE
and CT guidelines were in agreement. Traditional TEE sizing methods resulted in
33.3%(40/120) of valves being under sized (THV areaCT annular area) with a mean
annular over sizing of 9.417.4% (range: -21.5 to 65.9%) without annular rupture. In
contrast, the Vancouver CT sizing guidelines results in mean annular over sizing of
13.98.0% (range: 1.3-29.8%).
Conclusions: The Vancouver CT sizing guidelines enable standardized moderate over
expansion of the annulus that is likely to result in significantly lower rates of paravalvular
regurgitation.
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Background: Transcatheter aortic valve-in-valve (VIV) implantation is an emerging
therapeutic alternative for patients with failed surgical bioprosthesis and may obviate the
need for a redo surgery. We aimed to evaluate the clinical results of this technique using
a large worldwide registry.
Methods: The registry included 416 patients with degenerated aortic bioprosthetic valves
(age 77.7  9.7 years; 55.3% men) from 54 cardiac centers. The mode of failure was
stenosis (n168, 40.4%), regurgitation (n125, 30%), and combined stenosis and
regurgitation (n123, 29.6%). Implanted devices were Edwards SAPIEN (n225),
CoreValve (n190) and Melody (n1).
Results: Adverse procedural outcomes included 11.1% device malposition and 1.9%
ostial coronary obstruction. Post-procedure, valve maximum / mean gradients were 28.5 
14.3 mmHg / 16.1  9.0, respectively. Independent predictors for high post-
procedural gradients (mean 20 mmHg) were baseline bioprosthesis stenosis [vs.
regurgitation, odds ratio (OR), 6.33, p  0.001)] and the use of the Edwards SAPIEN
device (OR 2.1, p 0.008). At 30-day follow-up, all-cause mortality was 7.8% and
87.5% of patients were at New York Heart Association functional class I/II. One-year
survival was 82.6%. The strongest independent predictor for 1-year mortality post
VIV was baseline bioprosthesis stenosis (vs. regurgitation, OR 3.7, p0.003).
Conclusions: The VIV procedure is clinically effective in most patients, with 1-year
results comparable with other TAVR cohorts. Baseline bioprosthetic stenosis is the
strongest predictor for both elevated post-procedural gradients and 1-year mortality.
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Background: A novel, innovative transapical aortic valve implantation (TA-TAVI)
system completed enrollment (n90) in two pre-market studies. The TA device received
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CE Mark approval in September 2011 and to date over 100 commercial implants have been
performed. The device is composed of a porcine biologic valve attached to a self-expanding
nitinol stent designed for simple 2-step implantation and characterized by controlled position-
ing, self-seating in the native annulus resulting in a negligible paravalvular leak rate. The
device was tested in patients at high-risk for mortality with open surgical repair.
Methods: Ninety (90) patients (female69%) with severe aortic stenosis, a mean age of
83.4  4.1 years, all presenting with NYHA Functional Class III or IV and a mean STS
Score of 7.9  4.6 were enrolled in two studies in Germany at 6 centers. Patients are
clinically followed at 7 and 30 days, at 6 and 12 months, and annually thereafter out to
5 years post-implant. The device was successfully implanted in 94.4% of patients (n85)
with a pacemaker implantation rate of 11.1% (n10).
Results: At 12 months the survival rate is 81.1% (n73), the stroke rate is 4.4% (n4),
with no further re-intervention required on the implanted device since procedure. Of the
returning patients, 87% presented with NYHA Functional Class I/II. The mean gradient
at 6 months is 10.3 5.2 mmHg, the mean EOA is 1.5 0.4 cm2 and 77.3% of returning
patients suffered no paravalvular leak, 21.2% exhibit mild paravalvular leak (	1) and only
1 patient possesses a moderate paravalvular leak (	2).
Conclusions: These data confirm the safety profile at one year of this 2nd Generation
TAVI system. We will report the full 12 months results of this multi-center, non-
randomized study of this transapically-placed transcatheter aortic valve at TCT 2012.
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Background: Transcatheter aortic valve implantation (TAVI) has emerged as an
accepted treatment alternative for high risk patients with severe aortic stenosis. This study
was designed to evaluate the safety and efficacy of transapical aortic valve implantation
in high risk patients using the second generation JenaValve TAVI system. It consists of
a biological porcine valve mounted on a self-expanding Nitinol stent. Retrieval capability,
feeler guided anatomically positioning and clipping fixation on the diseased leaflets
provide potential advantages compared to current TAVI systems.
Methods: This study enrolled a total of 73 patients of whom 67 patients (mean age 83.13.9;
Euroscore 28.46.5) underwent elective TAVI at 7 German centers. Primary endpoint was all
cause mortality at 30 days. Procedural success, major adverse cerebrovascular and cardiac
events, functional improvement and echocardiographic valve performance were assessed at
baseline, post-procedure, discharge, 30 day, 3, 6, and 12 months.
Results: 60 of 67 patients underwent successful TAVI with the JenaValve resulting in a
procedural success of 89.6%. Pacemaker implantation for new onset conduction disorders
was necessary in 6 patients (9.1%). No coronary ostium obstructions were seen. TAVI
resulted in favorable reduction of mean transvalvular gradients (40.016.1mmHg vs.
10.07.3mmHg, p 0.0001) and increase in valve opening area (0.70.2cm2 vs.
1.70.6cm2, p 0.0001). None of the successful implanted patients had severe post
procedural aortic regurgitation ( grade 2). Survival at 30 days and 6 months was 92.4%
and 74.3% respectively. Stroke occurred in 4 patients (6.0%) at 6 months. NYHA Class
improved significantly at 6 months after valve implantation (5.4% NYHA class I, 56.8%
NYHA class II and 37.8% with class III). 12 months outcomes will be presented
according to VARC criteria at the conference.
Conclusions: TAVI using the JenaValve system has proven to be an effective treatment
option in high risk patients with aortic stenosis with good short and mid-term outcome.
Anatomically correct positioning and clip-fixation of the native leaflet led to good
hemodynamic function and favorably reduced paravalvular leak rates.
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Background: The Edwards SAPIEN valve has been FDA-approved with its Retroflex
delivery system for retrograde transfemoral (TF) treatment of inoperable patients with
severe aortic stenosis, and is the only device clinically available for transcatheter aortic
valve replacement (TAVR) in the United States (US). Because of insufficient iliofemoral
vascular access, many patients are excluded from the TF approach. We explored
transaortic (TAO) TAVR as an alternate access strategy for these patients.
Methods: Twenty-five consecutive patients underwent TAO TAVR between January
and April, 2012 at our site. All had symptomatic severe aortic stenosis, were inoperable,
and had inadequate vascular access for TF delivery. Through a small upper sternotomy
and direct insertion of the sheath into the ascending aorta, we delivered the valve using the
Retroflex catheter. Procedural and 30-day outcomes were retrospectively compared with
the first 25 patients treated by transapical (TA) access in our program.
Results: TAO TAVR was successfully performed in all patients. One perioperative death
occurred, which was unrelated to the TAO approach. No other cardiovascular death was
reported within 30 days. Compared with TA access, TAO TAVR had a similar all-cause
mortality rate at 30 days, and was associated lower incidence of bleeding events, as well
as shorter ICU length of stay.
BASELINE DEMOGRAPHICS
Trans-Aortic
Series
Trans-Apical
Series P-Value
Median Age (Years 	/SD) 83 (	/5) 85 (	/6) 0.35
Male Gender 10 (40%) 15 (60%) 0.26
Median STS Score (	/SD) 8 (	/4.4) 10.8 (	/3.27) 0.009
Operable for conventional
AVR
0% 100% 0.00
NYHA Class 3 & 4 24 (96%) 25 (100%) 1.00
Median AVA (cm2) 0.62 (	/0.15) 0.60 (	/0.12) 0.62
Median LVEF (%) 60 (	/16) 50 (	/15) 0.38
PROCEDURAL OUTCOMES*
Implantation Success 25 (100%) 25 (100%) 1.00
Moderate or Severe AI or PVL 1 (4%) 4 (16%) 0.35
Emergency open surgery 1 (4%) 1 (4%) 1.00
Procedural Mortality 1 (4%) 0 (0%) 1.00
30-DAY OUTCOMES*
Cardiovascular Mortality 1 (4%) 3 (12%) 0.61
All-Cause Mortality ** 5 (20%) 4 (16%) 1.00
Median ICU Length of Stay 3.0 (	/3.4) 6.0 (	/9.5) 0.013
Median Hospital Length of
Stay
7.0 (	/6.6) 11.0 (	/9.0) 0.069
Myocardial Infarction 0 (0%) 0 (0%) 1.00
Major Stroke 0 (0%) 1 (4%) 1.00
Minor Stroke 1 (4%) 0 (0%) 1.00
Major/Disabling Bleeding 3 (12%) 10 (40%) 0.05
Vascular Access
Complications
2 (8%) 2 (8%) 1.00
Acute Kidney Injury Stage 3 1 (4%) 0 (0%) 1.00
* Adjudicated using VARC criteria.
** 3 pneumonia-related respiratory failure, 1 C. difficile sepsis, 1 procedural death.
Conclusions: TAVR via the TAO approach, using the only commercially-available
device in the US, is technically feasible and is associated with favorable outcomes in
inoperable patients with severe aortic stenosis who are not candidates for TF access. In
these patients, the TAO approach expands the current alternative options for TAVR
access sites. Efforts directed towards enhancing the technologies and techniques associ-
ated with TAO TAVR should further improve the efficacy and safety of this procedure.
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Background: Transcatheter aortic valve replacement is recommended in inoperable
patients with severe, symptomatic aortic stenosis (AS), and is an accepted alternative to
surgical AVR in high risk patients. However, increased stroke, bleeding, vascular
complications and aortic regurgitation (AR) rates may adversely affect outcomes. The
repositionable and fully retrievable Lotus Valve is designed to facilitate accurate
positioning and minimize paravalvular leakage.
Methods: REPRISE I is a prospective, single-arm, 3-center feasibility study to assess
acute safety and performance in symptomatic patients with severe AS at high surgical risk.
The primary endpoint was clinical procedural success (successful implantation without
in-hospital major adverse cardiovascular and cerebrovascular events to discharge or 7
days, whichever came first).
Results: The Lotus Valve was implanted in 11 patients with mean STS and logistic
euroSCOREs of 4.92.5% and 9.54.4%, respectively, and high surgical risk due to
comorbidities/frailty (cognitive dysfunction in 5/11, gait speed 6s in 9/11, grip strength
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